Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer
Mené sur 1 207 patients atteints d'un cancer de la prostate résistant à la castration et de stade non métastatique, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans métastase et de la qualité de vie, de l'apalutamide en combinaison avec une thérapie anti-androgénique
In The Lancet Oncology, Fred Saad and colleagues show that health-related quality of life (HRQoL) among men with non-metastatic prostate cancer was not diminished with the addition of apalutamide to androgen deprivation therapy (ADT) in the SPARTAN trial. This finding is the latest in what appears to be a revolutionary wave in the approach to androgen deprivation therapy in the salvage setting for prostate cancer. In the RTOG-9601 study, men with increased prostate-specific antigen concentrations after radical prostatectomy but no evidence of metastatic disease were randomly assigned to receive salvage radiotherapy to the prostate bed with or without first-generation androgen-deprivation therapy, with results showing improvements in all clinical endpoints, including overall survival. The recently reported LATITUDE 3 and STAMPEDE 4 trials both enrolled men with castrate-sensitive metastatic disease (and some with very high-risk, locally-advanced disease) to traditional androgen deprivation therapy with or without abiraterone, and again there were improvements in all endpoints, including overall survival and quality of life.
The Lancet Oncology , commentaire, 2017